Alpine Immune Sciences, Inc

(NASDAQ:ALPN)

Latest On Alpine Immune Sciences, Inc (ALPN):

Date/Time Type Description Signal Details
2023-05-12 06:01 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.28 beats by $0.09, revenue of $9.4M beats by $2.52MN/A
2023-03-29 08:50 ESTNewsAlpine Immune: Rebuilding Itself From Scratch, But Long Way To Go Before ProofN/A
2023-03-24 06:33 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.41 misses by $0.14, revenue of $2.78M misses by $8.18MN/A
2023-03-24 06:33 ESTNewsAlpine Immune Sciences, Inc. (ALPN) Q4 2022 Earnings Call TranscriptN/A
2023-03-22 23:18 ESTNewsAlpine Immune Sciences Q4 2022 Earnings PreviewN/A
2023-01-19 15:46 ESTNewsAlpine Immune wins bullish views at Morgan Stanley on lead programN/A
2022-11-14 22:08 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.42 misses by $0.32, revenue of $8.37M misses by $10.31MN/A
2022-11-14 22:08 ESTNewsAlpine Immune Sciences, Inc. (ALPN) Q3 2022 Earnings Call TranscriptN/A
2022-11-12 00:39 ESTNewsAlpine Immune Sciences Q3 2022 Earnings PreviewN/A
2022-10-27 21:26 ESTNewsAlpine: Ramifications Of The Davoceticept TerminationN/A
2022-10-27 21:25 ESTNewsAlpine Immune Sciences: ALPN-202 May Be Dead, But The Company Isn'tN/A
2022-10-24 18:20 ESTNewsAlpine Immune ends enrollments for cancer studies after patient deathN/A
2022-09-21 04:34 ESTNewsAlpine Immune Sciences drops 13% after hours on $100M stock offeringN/A
2022-09-21 04:34 ESTNewsAlpine Immune Sciences prices $100M stock offeringN/A
2022-08-11 22:35 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.60 misses by $0.21, revenue of $5.29M misses by $4.75MN/A
2022-08-10 12:06 ESTNewsEvotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303N/A
2022-06-08 00:04 ESTNewsAndrew S. Sandler is the new chief medical officer of Alpine ImmuneN/A
2022-05-24 13:14 ESTNewsFDA lifts partial clinical hold on Alpine Immune's davoceticept for malignanciesN/A
2022-05-13 06:49 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.25, revenue of $13.63MN/A
2022-04-25 17:20 ESTNewsAlpine: Rest Before Rallying AgainN/A
2022-03-18 11:15 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.52 misses by $0.22, revenue of $4.53M misses by $9.44MN/A
2022-03-07 15:24 ESTNewsPartial clinical hold placed on Alpine Immune's davoceticept for malignanciesN/A
2021-12-16 22:17 ESTNewsAlpine Immune, Horizon Therapeutics team up to develop therapies for autoimmune and inflammatory diseasesN/A
2021-11-11 00:43 ESTNewsAlpine Immune Sciences EPS misses by $0.56, misses on revenueN/A
2021-09-22 20:46 ESTNewsMRIN, ALPN, SMMT and LPTX among after hours moversN/A
2021-09-17 12:49 ESTNewsAlpine Immune secures $91M through equity offeringN/A
2021-08-12 11:57 ESTNewsAlpine Immune Sciences (ALPN) Investor PresentationN/A
2021-08-11 15:56 ESTNewsAlpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-10 19:56 ESTNewsAlpine Immune Sciences EPS misses by $0.12, misses on revenueN/A
2021-07-20 18:38 ESTNewsAlpine Immune Sciences files for $150M mixed shelf offeringN/A
2021-07-20 18:35 ESTNewsAlpine Immune Sciences: Better Days AheadN/A
2021-07-20 18:33 ESTNewsAlpine Immune releases promising early data on lupus candidateN/A
2021-07-20 18:22 ESTNewsAlpine Immune shares rise on clinical trial collaboration agreement with MerckN/A
2021-04-16 08:52 ESTNewsAlpine Immune Sciences Is A Blind Buy After The Recent Price DecreaseN/A
2021-03-19 11:35 ESTNewsAlpine Immune Sciences EPS beats by $0.04, beats on revenueN/A
2021-03-19 11:29 ESTNewsAlpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-19 04:07 ESTEarnings EstimateAn EPS average of -$0.86 is estimated for the 2022 year.Sell
2021-03-19 04:07 ESTEarnings EstimateAn EPS average of -$0.27 is estimated for the quarter ending on June 30, 2021.N/A
2021-01-06 02:19 ESTNewsAlpine: Is This A Young Oak Tree?N/A
2020-12-22 19:05 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.5 to $21.4.Neutral
2020-12-13 03:09 ESTFinancialsCompany financials have been released.Neutral
2020-12-11 15:07 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 11:12 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 11:05 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 20:38 ESTNewsAlpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-13 03:09 ESTEarnings EstimateAn EPS average of -$0.08 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-12 16:24 ESTNewsAlpine Immune Sciences EPS misses by $0.05, misses on revenueN/A
2020-11-01 16:57 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 04:09 ESTFinancialsCompany financials have been released.Neutral
2020-08-22 04:04 ESTFinancialsCompany financials have been released.Neutral

About Alpine Immune Sciences, Inc (ALPN):

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

ALPN Quotes by TradingView

See Advanced Chart

General

  • Name Alpine Immune Sciences, Inc
  • Symbol ALPN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 53
  • Last Split Factor1:4
  • Last Split Date2017-07-25
  • Fiscal Year EndDecember
  • IPO Date2015-06-17
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.alpineimmunesciences.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 59.37
  • Price/Book (Most Recent Quarter) 4.91
  • Enterprise Value Revenue 46.44
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate -$0.73
  • Next Year EPS Estimate -$0.86
  • Next Quarter EPS Estimate -$0.26
  • Operating Margin -640%
  • Return on Assets -17%
  • Return on Equity -54%
  • Revenue 4.58 million
  • Earnings Per Share -$2.97
  • Revenue Per Share $0.23
  • Gross Profit -34107000
  • Quarterly Earnings Growth 561.9%
View More

Highlights

  • Market Capitalization 328.72 million
  • EBITDA -48231000
  • Analyst Target Price $21.4
  • Book Value Per Share $2.83
View More

Share Statistics

  • Shares Outstanding 23.8 million
  • Shares Float 8.66 million
  • % Held by Insiders 2849%
  • % Held by Institutions 52.56%
  • Shares Short 385513
  • Shares Short Prior Month 377164
  • Short Ratio 2.78
  • Short % of Float 4%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 1.73
  • 52 Week High $16.37
  • 52 Week Low $2.1
  • 50 Day Moving Average 12.51
  • 200 Day Moving Average 10.57
View More

Dividends

  • Dividend Date 2017-07-25
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Alpine Immune Sciences, Inc (ALPN) Dividend Calendar:

ALPN's last dividend payment was made to shareholders on July 25, 2017.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Alpine Immune Sciences, Inc (ALPN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31-$0.27-$0.3112.9%
2020-09-302020-11-12$1.91 million-$0.28-$0.23-20.43%
2020-06-302020-08-11$N/A-$0.53$0.54-199.07%
2020-03-312020-05-14$1.09 million-$0.30-$0.4736.17%
2019-12-312020-03-30$884000-$0.33-$0.5943.59%
2019-09-302019-11-13$289000-$0.62-$0.688.82%
2019-06-302019-08-13$567000-$0.64-$0.685.54%
2019-03-312019-05-09$N/A-$0.70-$0.69-1.45%
2018-12-312019-03-18$705000-$0.80-$0.80-0.25%
2018-09-302018-11-08$-390000-$0.88-$0.57-55.48%
2018-06-302018-08-09$390000-$0.57-$0.43-31.55%
2018-03-312018-05-14$315000-$0.38-$0.403.8%
2017-12-312018-03-28$1.6 million-$0.33-$0.379.59%
2017-09-302017-11-13$128000$0.18-$0.28164.29%
2017-06-302017-09-29$738000-$5.40-$2.19-146.58%
2017-03-312017-05-01$737000-$2.28-$1.90-20%
2016-12-312017-02-13$2.95 million-$2.00-$2.209.09%
2016-09-302016-11-07$N/A-$1.92-$2.3718.99%
2016-06-302016-08-01$N/A-$2.20-$2.09-5.26%
2016-03-312016-05-02$N/A-$2.04-$1.76-15.91%
2015-12-312016-02-29-$1.68-$1.43-17.48%
2015-09-302015-11-02$N/A-$1.56-$1.666.02%
2015-06-302015-08-03$N/A-$1.41-$0.41-243.9%

Alpine Immune Sciences, Inc (ALPN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development 6.16 million N/A 4.88 million 5.8 million 9.53 million
Income Before Tax -6.14 million N/A -5.53 million -6.14 million -11.48 million
Selling General Administrative 2.73 million N/A 1.78 million 2.1 million 2.47 million
Gross Profit N/A N/A N/A N/A 289000
Ebit -5.78 million N/A -5.28 million -6 million -11.71 million
Operating Income -6.97 million N/A -5.57 million -7.02 million -11.71 million
Income Tax Expense N/A -6000 N/A N/A N/A
Total Revenue 1.91 million N/A 1.09 million 884000 289000
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net 1.04 million N/A N/A 812000 235000
Net Income From Continuing Operations -6.14 million N/A -5.53 million -6.14 million -11.48 million
Net Income Applicable to Common Shares -6.14 million -9.93 million N/A -6.14 million -11.48 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments 1.84 million 9.06 million 13.13 million 4.39 million N/A
Change to Liabilities -472000 N/A N/A -5.41 million N/A
Total Cash Flow from Investing Activities 1.84 million N/A N/A 4.39 million N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 56.39 million 2000 5 million N/A N/A
Change to Operating Activities 39000 N/A N/A 5.71 million N/A
Change in Cash 52.86 million 63.64 million 8.32 million -1.27 million N/A
Total Cash from Operating Activities -5.39 million 54.52 million -9.69 million -5.67 million N/A
Depreciation 140000 144000 135000 -575000 N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 1.04 million N/A N/A 751000 N/A
Capital Expenditures 60000 198000 56000 486000 N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities 86.57 million N/A 24.99 million 24.62 million 29.91 million
Total Stockholder Equity 67.47 million N/A 24.86 million 29.47 million 34.83 million
Other Current Liabilities 28.51 million N/A N/A N/A 13.67 million
Total Assets 154.03 million N/A 49.85 million 54.09 million 64.74 million
Common Stock 24000 16.23 million N/A 19000 34.83 million
Other Current Assets N/A N/A N/A N/A 5.87 million
Retained Earnings -109.52 million N/A -93.46 million -87.93 million N/A
Other Liabilities 29.99 million 58.29 million N/A N/A 16.24 million
Other Assets 254000 11.46 million N/A 254000 12.29 million
Cash 141.08 million N/A 24.45 million 16.12 million 17.4 million
Total Current Liabilities 35.85 million N/A 5.11 million 8.68 million 13.67 million
Other Stockholder Equity -41000 N/A N/A 10000 N/A
Property, Plant & Equipment 11.23 million N/A N/A 11.54 million N/A
Total Current Assets 142.55 million N/A 38.09 million 42.3 million 52.45 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 67.47 million 16.23 million N/A 29.47 million 34.83 million
Short Term Investments N/A N/A 11.24 million 24.4 million 29.19 million
Long Term Debt 8.74 million N/A 8.17 million 4.51 million N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 742000 N/A 468000 1.54 million N/A

Alpine Immune Sciences, Inc (ALPN) Chart:

Alpine Immune Sciences, Inc (ALPN) News:

Below you will find a list of latest news for Alpine Immune Sciences, Inc (ALPN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Alpine Immune Sciences, Inc (ALPN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ALPN Trades:

Date Shares Price
Jun 13, 2022 7:57 PM EST19$8.61
Jun 13, 2022 7:57 PM EST6$8.6
Jun 13, 2022 7:57 PM EST100$8.61
Jun 13, 2022 7:59 PM EST15$8.585
Jun 13, 2022 7:59 PM EST1$8.585

Alpine Immune Sciences, Inc (ALPN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320018177/0000899243-20-018177-index.htm
2020-07-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1626199/000000000020006420/0000000000-20-006420-index.htm
2020-08-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1626199/000000000020007443/0000000000-20-007443-index.htm
2018-04-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924318010650/0000899243-18-010650-index.htm
2018-04-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924318010652/0000899243-18-010652-index.htm
2018-08-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924318021736/0000899243-18-021736-index.htm
2018-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924318021737/0000899243-18-021737-index.htm
2018-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924318025713/0000899243-18-025713-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000496/0000899243-19-000496-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000497/0000899243-19-000497-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000498/0000899243-19-000498-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000499/0000899243-19-000499-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000500/0000899243-19-000500-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000503/0000899243-19-000503-index.htm
2019-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319001661/0000899243-19-001661-index.htm
2019-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319001662/0000899243-19-001662-index.htm
2019-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319001663/0000899243-19-001663-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319003030/0000899243-19-003030-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319003031/0000899243-19-003031-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319003032/0000899243-19-003032-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319003038/0000899243-19-003038-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319015346/0000899243-19-015346-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000637/0000899243-20-000637-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000638/0000899243-20-000638-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000639/0000899243-20-000639-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000640/0000899243-20-000640-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000641/0000899243-20-000641-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000642/0000899243-20-000642-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000643/0000899243-20-000643-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320002067/0000899243-20-002067-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320002068/0000899243-20-002068-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320002069/0000899243-20-002069-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320018172/0000899243-20-018172-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320018173/0000899243-20-018173-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320018177/0000899243-20-018177-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320018864/0000899243-20-018864-index.htm
2019-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000091957419001006/0000919574-19-001006-index.htm
2019-01-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626199/000092189519000160/0000921895-19-000160-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626199/000092189520000527/0000921895-20-000527-index.htm
2018-01-26SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000094787118000053/0000947871-18-000053-index.htm
2018-01-26SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000094787118000060/0000947871-18-000060-index.htm
2019-01-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000094787119000042/0000947871-19-000042-index.htm
2019-01-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000094787119000043/0000947871-19-000043-index.htm
2019-01-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000094787119000044/0000947871-19-000044-index.htm
2020-07-30SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000094787120000655/0000947871-20-000655-index.htm
2019-01-24SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000114420419002677/0001144204-19-002677-index.htm
2018-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518098445/0001193125-18-098445-index.htm
2018-03-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000119312518098624/0001193125-18-098624-index.htm
2018-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1626199/000119312518127697/0001193125-18-127697-index.htm
2018-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626199/000119312518127706/0001193125-18-127706-index.htm
2018-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518127833/0001193125-18-127833-index.htm
2018-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518162515/0001193125-18-162515-index.htm
2018-06-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1626199/000119312518189391/0001193125-18-189391-index.htm
2018-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518189404/0001193125-18-189404-index.htm
2018-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518192903/0001193125-18-192903-index.htm
2018-06-21S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000119312518199598/0001193125-18-199598-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518238992/0001193125-18-238992-index.htm
2018-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518281909/0001193125-18-281909-index.htm
2019-01-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312519010606/0001193125-19-010606-index.htm
2019-01-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312519012912/0001193125-19-012912-index.htm
2019-01-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119312519014154/0001193125-19-014154-index.htm
2019-01-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119312519014248/0001193125-19-014248-index.htm
2019-02-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312519032222/0001193125-19-032222-index.htm
2020-07-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119312520204703/0001193125-20-204703-index.htm
2020-08-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119312520206868/0001193125-20-206868-index.htm
2020-08-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119312520206870/0001193125-20-206870-index.htm
2020-08-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626199/000119312520211999/0001193125-20-211999-index.htm
2018-08-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119380518001083/0001193805-18-001083-index.htm
2019-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000120919119004779/0001209191-19-004779-index.htm
2019-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000120919119004783/0001209191-19-004783-index.htm
2019-01-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000120919119005067/0001209191-19-005067-index.htm
2019-01-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000120919119005068/0001209191-19-005068-index.htm
2019-01-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000120919119005069/0001209191-19-005069-index.htm
2018-03-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/0001564590-18-006916-index.htm
2018-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619918000004/0001626199-18-000004-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619918000010/0001626199-18-000010-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619918000012/0001626199-18-000012-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619918000016/0001626199-18-000016-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619918000018/0001626199-18-000018-index.htm
2019-01-30DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000001/0001626199-19-000001-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000007/0001626199-19-000007-index.htm
2019-03-1810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626199/000162619919000010/0001626199-19-000010-index.htm
2019-03-18S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1626199/000162619919000012/0001626199-19-000012-index.htm
2019-03-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000014/0001626199-19-000014-index.htm
2019-03-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000016/0001626199-19-000016-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000019/0001626199-19-000019-index.htm
2019-04-02CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000022/0001626199-19-000022-index.htm
2019-04-05424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1626199/000162619919000024/0001626199-19-000024-index.htm
2019-04-11PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000026/0001626199-19-000026-index.htm
2019-04-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000029/0001626199-19-000029-index.htm
2019-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000034/0001626199-19-000034-index.htm
2019-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000035/0001626199-19-000035-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000038/0001626199-19-000038-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619919000040/0001626199-19-000040-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000043/0001626199-19-000043-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000046/0001626199-19-000046-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000049/0001626199-19-000049-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000053/0001626199-19-000053-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619919000055/0001626199-19-000055-index.htm
2019-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000060/0001626199-19-000060-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000064/0001626199-19-000064-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619919000067/0001626199-19-000067-index.htm
2020-01-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000003/0001626199-20-000003-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000008/0001626199-20-000008-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626199/000162619920000009/0001626199-20-000009-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000011/0001626199-20-000011-index.htm
2020-05-05DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000014/0001626199-20-000014-index.htm
2020-05-05DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000015/0001626199-20-000015-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000019/0001626199-20-000019-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619920000020/0001626199-20-000020-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000024/0001626199-20-000024-index.htm
2020-06-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000026/0001626199-20-000026-index.htm
2020-06-188-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000030/0001626199-20-000030-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000031/0001626199-20-000031-index.htm
2020-07-08S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1626199/000162619920000033/0001626199-20-000033-index.htm
2020-07-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000035/0001626199-20-000035-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000037/0001626199-20-000037-index.htm
2020-08-07DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000038/0001626199-20-000038-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000043/0001626199-20-000043-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619920000045/0001626199-20-000045-index.htm
2020-08-11S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1626199/000162619920000047/0001626199-20-000047-index.htm
2020-08-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000049/0001626199-20-000049-index.htm
2020-08-19424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1626199/000162619920000052/0001626199-20-000052-index.htm
2019-04-04EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1626199/999999999519000606/9999999995-19-000606-index.htm
2020-07-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1626199/999999999520001835/9999999995-20-001835-index.htm
2020-08-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1626199/999999999520002196/9999999995-20-002196-index.htm
2019-03-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1626199/999999999719001523/9999999997-19-001523-index.htm
2019-03-29CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1626199/999999999719002103/9999999997-19-002103-index.htm

Alpine Immune Sciences, Inc (ALPN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alpine Immune Sciences, Inc (ALPN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2849%
Institutional Ownership: 5256%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-05-30James Paul RickeySenior VP and CFOBuy10,000.004.9549,500.0010,000.00https://www.sec.gov/Archives/edgar/data/1626199/000089924319015346/0000899243-19-015346-index.htm
2019-02-08MANAGEMENT L.L.C. TIGER10% Share HolderSell25,000.005.85146,245.00137,728.00https://www.sec.gov/Archives/edgar/data/1626199/000091957419001006/0000919574-19-001006-index.htm
2019-01-18Frazier Life Sciences VIII, L.P.10% Share HolderBuy372,439.005.371,999,997.432,571,450.00https://www.sec.gov/Archives/edgar/data/1626199/000120919119004783/0001209191-19-004783-index.htm
2019-01-18James N TopperDirectorBuy372,439.005.371,999,997.432,571,450.00https://www.sec.gov/Archives/edgar/data/1626199/000120919119004779/0001209191-19-004779-index.htm
2020-01-23James Paul RickeySenior VP and CFOBuy18,543.0028,543.00https://www.sec.gov/Archives/edgar/data/1626199/000089924320002069/0000899243-20-002069-index.htm
2019-01-18Xiangmin CuiDirectorBuy3,165,735.005.3716,999,996.953,165,735.00https://www.sec.gov/Archives/edgar/data/1626199/000120919119005069/0001209191-19-005069-index.htm
2020-01-23STANFORD L PENGPresident & Head of R&DBuy32,217.0032,217.00https://www.sec.gov/Archives/edgar/data/1626199/000089924320002068/0000899243-20-002068-index.htm
2019-01-18ORBIMED ADVISORS LLCDirectorBuy372,439.005.371,999,997.433,670,955.00https://www.sec.gov/Archives/edgar/data/1626199/000094787119000043/0000947871-19-000043-index.htm
2019-01-18Peter A. ThompsonDirectorBuy372,439.005.371,999,997.433,670,955.00https://www.sec.gov/Archives/edgar/data/1626199/000094787119000044/0000947871-19-000044-index.htm
2019-01-18Alpine ImmunoSciences, L.P.10% Share HolderBuy190,875.005.371,024,998.753,994,781.00https://www.sec.gov/Archives/edgar/data/1626199/000089924319001663/0000899243-19-001663-index.htm
2019-01-18Jay VenkatesanDirectorBuy190,875.005.371,024,998.753,994,781.00https://www.sec.gov/Archives/edgar/data/1626199/000089924319001661/0000899243-19-001661-index.htm
2019-01-18MITCHELL GOLDExecutive Chairman and CEOBuy190,875.005.371,024,998.753,994,781.00https://www.sec.gov/Archives/edgar/data/1626199/000089924319001662/0000899243-19-001662-index.htm
2020-01-23MITCHELL GOLDExecutive Chairman and CEOBuy67,569.0068,861.00https://www.sec.gov/Archives/edgar/data/1626199/000089924320002067/0000899243-20-002067-index.htm